Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. ABUS
ABUS logo

ABUS Earnings

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Quarterly Results

ABUS logo
ABUS
2025-11-12
Revenue
$0
(est)
-
EPS
-
AI Prediction
-
Calendar ReportReport
ABUS logo
ABUS
2025-07-31 07:30:00
pre market
Pre-Market
Revenue
$1.80M
(est)
-
EPS
$0.02(est)
AI Prediction
-
ABUS logo
ABUS
2025-05-08
Revenue
$0
(est)
-
EPS
$0.09(est)
AI Prediction
-

ABUS Earnings Forecast

Looking ahead, ABUS remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 599.59K and an EPS of -0.03.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been unchanged by 0%, while EPS estimates have been unchanged by 0%. For the upcoming Q4 2025, revenue estimates have been adjusted unchanged by 0%. These revisions correlate with a -8.28% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in ABUS long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
1Y
3Y
5Y
Currency: USD
Currency: USD
--
Revenue Estimate-:0
--
EPS Estimate-:0
—
Stock Price0
Revenue Estimates for FY2025
No Change
down
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down
0.00%
In Past 3 Month
Revenue Estimates for Q4 2025
No Change
down
0.00%
In Past 3 Month
Stock Price
Go Down
down
-8.28%
In Past 3 Month

Earnings Forecast

Revenue
EPS
Currency: USD
Actual
Estimate
AI Analysis

Earnings Surprise Analysis

Revenue
EPS
1Y
3Y
AI Analysis
Earnings Reaction
The chart below shows how ABUS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ABUS sees a 1.81% change in stock price 10 days leading up to the earnings, and a -2.21% change 10 days following the report. On the earnings day itself, the stock moves by 0.7%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed -5.79% on the day following the earnings release and then changed by -8.88% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.

People Also Watch

Frequently Asked Questions

What were the key highlights of ABUS's latest earnings report for ?

ABUS reported its earnings on 2025-11-12, showcasing a revenue of against an estimate of , resulting in a 0% surprise. The EPS was 0, surpassing the expected 0 by 0%. The stock experienced a 2.44% price change on the earnings day and a 2% change over the next five days, reflecting market reactions to the results.

How did ABUS's stock price react after the earnings release?

Following ABUS's earnings announcement on 2025-11-12, the stock price moved by 2.44% on the day of the release. Over the subsequent five days, it saw a 2% change. Historically, ABUS's stock price tends to shift by an average of 1.81% in the 10 days leading up to earnings and -2.21% in the 10 days following, providing insight into potential market.

What are the revenue and EPS estimates for ABUS for 2025/Q4?

For 2025/Q4, analysts estimate ABUS's annual revenue to reach 599.59K, while the EPS is projected at -0.03. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

How does ABUS's stock price correlate with earnings forecast revisions?

The correlation between ABUS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

What should investors expect from ABUS's next earnings report?

Based on historical trends, ABUS's stock price typically moves by 1.81% in the 10 days before its earnings and -2.21% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.03 and revenue of 599.59K.

What is the sentiment in Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Summary?

The earnings call summary indicates a stable financial position with a sufficient cash runway and ongoing clinical trials. However, concerns arise from management's vague responses in the Q&A, regulatory risks, competitive pressures, and ongoing litigation. Despite a strong cash position and strategic focus, these uncertainties likely balance out any potential positive sentiment, leading to a neutral outlook for the stock price over the next two weeks.